NeurologyLive Friday 5 — June 4, 2021

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 4, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: American Headache Society's 63rd Annual Scientific Meeting

The NeurologyLive team is providing live coverage of the ongoing AHS 2021 Annual Meeting, including interviews with opinion leaders and presenters, as well as updates on the latest headache and migraine science and study findings being presented at the conference.

2: Mind Moments Ep. 38: Advancing MS Care and Awareness

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Matthew B. Harms, MD, a neurologist at Banner Health and chief medical officer of the MS Association of America, about the importance that awareness efforts like World MS Day play in the advancing of care, as well as how the approach to treating MS has evolved over the years that he's spent treating patients.

3: NeuroVoices: Eric Leuthardt, MD, on Expanding and Streamlining the IpsiHand System

The founder and chief scientific officer of Neurolutions discussed other populations that may benefit from the IpsiHand Upper Extremity Rehabilitation System by building on its current capabilities, including how it can impact key cognitive and functional deficits, as well as how it can be acclimated into regular clinical care.

4: Peer Exchange: Monitoring Treatment Response in Relapsing-Remitting MS

In this segment of the Peer Exchange, "Strategies in Treating Relapsing-Remitting Multiple Sclerosis," Scott Newsome, DO, MSCS, FAAN; Patricia K. Coyle, MD; Robert Fox, MD; and Clyde E. Markowitz, MD, offer recommendations regarding how to monitor patients who receive therapy for relapsing-remitting multiple sclerosis and to conduct repeat imaging assessments appropriately.

5: Paper Calls for Improved Trial Design for Alzheimer Disease, Dementia-Related Studies

An advisory panel of experts convened by the Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) noted that recommendations for exploratory trial designs may help clinicians be more confident in making the all-important go/no-go decisions about advancing drugs to larger later-stage trials.

–––––––––

If you missed your chance to see the May broadcast of our free webinar series, "The Ever-Changing Face of Multiple Sclerosis," put on in partnership with the Consortium of Multiple Sclerosis Centers, don't fret! You can join Ahmed Obeidat, MD, PhD; Mitch Freedman, MD; and Suma Shah, MD, and others as they discuss the evolution of therapeutics for the treatment of multiple sclerosis. Additionally, you can register for the live broadcast of the third installment on June 16, 2021, for a detailed discussion on the evolution of diagnosis and treating multiple sclerosis care during a pandemic featuring Obeidat; Anne Cross, MD; and Gloria von Geldern, MD.

To register for the next broadcast for free, click here.

To view the enduring version of either of the first two programs, click here for our Future Leaders in Neurology section.